Our findings indicate IRE1α-XBP1s signaling is a potential therapeutic target and provides strong evidence to support the use of EGFR targeting in combination with chemotherapeutics for the treatment of colorectal cancer. The gene discussed is EGFR; the disease is colorectal cancer.